IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

Pulmonary fibrosis is a condition where lung tissue becomes thick, stiff, and scarred over time. This scarring makes it difficult for the lungs to transfer oxygen into the blood, leading to symptoms like breathlessness and a persistent cough. Idiopathic pulmonary fibrosis (IPF) is the most common form, but scarring can also worsen in other types, known as progressive pulmonary fibrosis. Currently, treatments can slow down scarring, but new and better options are urgently needed.

This study is testing an investigational medicine called admilparant (also known as BMS-986278). The drug works by blocking a specific signal in the body called LPA1, which is believed to play a key role in building up scar tissue in the lungs. By turning down this signal, researchers hope the medicine might help protect the lungs from further damage.

Because this is an 'extension study', it is designed to see what happens when people take admilparant over an extended period. In this type of trial, there is no dummy pill (placebo), so every participant receives the real medicine. Doctors will closely monitor participants to ensure the treatment remains safe and well tolerated over months and years.

By following participants over time, the research team will collect important information about any side effects, as well as regular checks on blood, vital signs, and heart health. This helps scientists understand whether admilparant could provide safe, lasting support for people living with lung fibrosis.